Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity
- 1 December 2005
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 110 (1) , 119-129
- https://doi.org/10.1016/j.jconrel.2005.09.028
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Immunoregulatory T cells in tumor immunityCurrent Opinion in Immunology, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Polymeric anticancer drugs with pH-controlled activationAdvanced Drug Delivery Reviews, 2004
- Antibody-targeted HPMA copolymer-bound anthracycline antibioticsDrugs of the Future, 2003
- HPMA copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activityPublished by Elsevier ,2002
- Differences in the intracellular fate of free and polymer-bound doxorubicinJournal of Controlled Release, 2002
- Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomesJournal of Controlled Release, 2001
- New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological propertiesJournal of Controlled Release, 2001
- Polymeric drugs based on conjugates of synthetic and natural macromoleculesJournal of Controlled Release, 2000
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982